CLINICAL_TRIALS
trial_result
· 2013-09-09
Clinical Trial Update: A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial [Phase 2]
Summary
Phase 2 trial assessing lenalidomide for mantle cell lymphoma after bortezomib failure or progression; results posted in 2013.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Celgene | Conditions: Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-09-09